Adverum Biotechnologies Inc
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is … Read more
Adverum Biotechnologies Inc - Asset Resilience Ratio
Adverum Biotechnologies Inc (ADVM) has an Asset Resilience Ratio of 0.00% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Adverum Biotechnologies Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Adverum Biotechnologies Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Adverum Biotechnologies Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Adverum Biotechnologies Inc Industry Peers by Asset Resilience Ratio
Compare Adverum Biotechnologies Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Adverum Biotechnologies Inc (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Adverum Biotechnologies Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 36.16% | $65.04 Million | $179.84 Million | +22.35pp |
| 2023-12-31 | 13.82% | $21.53 Million | $155.77 Million | -24.17pp |
| 2022-12-31 | 37.99% | $117.16 Million | $308.37 Million | -23.64pp |
| 2021-12-31 | 61.63% | $270.99 Million | $439.73 Million | -14.49pp |
| 2020-12-31 | 76.11% | $367.31 Million | $482.57 Million | +31.15pp |
| 2019-12-31 | 44.96% | $100.14 Million | $222.73 Million | +21.48pp |
| 2018-12-31 | 23.48% | $50.13 Million | $213.50 Million | -35.94pp |
| 2017-12-31 | 59.42% | $119.97 Million | $201.91 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $234.58 Million | -- |
| 2015-12-31 | 14.28% | $37.73 Million | $264.32 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $161.91 Million | -- |